Overview

Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

Status:
Not yet recruiting

Trial end date:
2030-09-01

Target enrollment:

Participant gender:

Summary

This study is a treatment protocol with blinatumomab for infants under 1 year old who are diagnosed with acute lymphoblastic leukemia with a specific unfavorable genetic alteration. The purpose of the study is to improve the outcome of this disease in infants.

Phase:

Phase 3

Details

Lead Sponsor:

Princess Maxima Center for Pediatric Oncology

Collaborators:

Amgen Europe B.V
University of Milano Bicocca

Treatments:

Antibodies, Bispecific
Blinatumomab